---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-282407"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:14:45.350970+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience sells subsidiary for $100M, licenses ADC programs, raises $100M PIPE

## Summary
- Sells wholly owned subsidiary Private Aadi to Kaken Investments for $100M; stockholder approval required.
- Licenses three pre-clinical ADC programs (MUC16, PTK7, SEZ6) from WuXi Biologics; upfront $44M total.
- Raises $100M via PIPE: 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.
- Appoints Baiteng Zhao, Ph.D. (ex-ProfoundBio CEO) to Board; he committed $3M in PIPE.
- Stockholder support agreements secured for ~36% of shares; termination fee $3.5M.

## SEC filing metadata
- accession: 0001193125-24-282407
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/0001193125-24-282407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/d891246d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-282407
- JSON: https://secwatch.observer/filing/0001193125-24-282407.json
- Plain text: https://secwatch.observer/filing/0001193125-24-282407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.